AAX Biotech AB
PrivateLast Round
VC Round
Feb 19, 2026
Momentum
Top 50%
of companies Caplight tracks
Company Overview
AAX Biotech AB operates in Healthcare & Life Sciences and is based in Stockholm. Its latest recorded funding round was a VC Round in February 2026.
AAX Biotech AB is a biotechnology company that develops proprietary antibody engineering technologies, including Seqitope and Opti-mAb, to improve the performance and developability of next-generation antibody therapeutics.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
AAX Biotech AB Comparables
Compare AAX Biotech AB with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| ProteoGenix | 76% | |
| AvantGen, Inc. | 76% | |
| Adimab | 72% |
For institutional investors. Book with your work email.
AAX Biotech AB Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Feb 19, 2026 | ||||
| VC Round | Oct 2, 2024 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
AAX Biotech AB Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Trio Impact Invest | VC Round |
| Phase2Phase Biopharma | VC Round |
| Life Science Invest | VC Round |
| Northislet AB | VC Round |
| Karolinska Institutet Holding | VC Round |
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 19, 2026
$555K round led by Trio Impact Invest
- Nov 11, 2025
Presenting a poster at PEGS Europe in Lisbon, November 11-13, 2025.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingNov 11, 2026
On Nov 11th '26, AAX Biotech AB and Discovery Evolution announce a research collaboration to discover and develop bispecific antibody candidates for oncology, combining antibody engineering with digital antibody discovery to generate candidates for further preclinical evaluation.
- partners_withNov 11, 2026
On Nov 11th '26, AAX Biotech AB and Discovery Evolution announce a research collaboration to discover and develop bispecific antibody candidates for oncology, combining antibody engineering with digital antibody discovery for further preclinical evaluation.
- hiresNov 5, 2026
AAX Biotech AB appoints Sarah Fredriksson as CEO on Nov 5th '26.
- attends_eventSep 11, 2026
AAX Biotech AB was selected as the winner of the Nordic Star 2026 Pitch Competition at NLSDays 2026, held in Sweden on Sep 8th-9th '26.
- recognized_asSep 10, 2026
The Nordic Life Science Days jury selects AAX Biotech AB as the winner of the Nordic Star Pitch Competition and the NLSDays Nordic Star 2026 Award at the 2026 event in Sweden.
For institutional investors. Book with your work email.
AAX Biotech AB Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about AAX Biotech AB's valuation, stock price, and market status.
Is AAX Biotech AB a public or private company?
AAX Biotech AB is a private company.
What is the current stock price of AAX Biotech AB?
AAX Biotech AB is a private company, so its shares have no public market price. Caplight tracks AAX Biotech AB's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is AAX Biotech AB worth (valuation)?
Valuation information for AAX Biotech AB is not publicly available.
Can I buy AAX Biotech AB stock?
AAX Biotech AB shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was AAX Biotech AB's last funding round?
AAX Biotech AB's most recent funding round was VC Round on February 19, 2026.
Who are the main investors in AAX Biotech AB?
Key investors in AAX Biotech AB include Trio Impact Invest.
Will AAX Biotech AB IPO soon?
No public IPO plans have been announced for AAX Biotech AB.
How can I track AAX Biotech AB secondary market activity?
Caplight tracks bids, offers, and trades in AAX Biotech AB's shares on secondary markets.